Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least 24 months

• BMI between 18 and 30 kg/m2

• Insulin naive subjects

• OAD treatment with max two OADs alone or combined with other therapy

• HbA1c between 7-12%

Exclusion Criteria:

• Type 1 diabetes

• Receipt of any investigational drug within the last three months prior to this trial

• Current or previous treatment with thiazolidiones within the last 6 months

• OAD treatment with three or more OADs within the last 4 months